804 related articles for article (PubMed ID: 215136)
21. Calcium-dependent proteolytic stimulation of adenylate cyclase in platelets from spontaneously hypertensive rats.
Tremblay J; Hamet P
Metabolism; 1984 Aug; 33(8):689-95. PubMed ID: 6087083
[TBL] [Abstract][Full Text] [Related]
22. Platelet aggregation. II. Adenyl cyclase, prostaglandin E1, and calcium.
Vigdahl RL; Marquis NR; Tavormina PA
Biochem Biophys Res Commun; 1969 Oct; 37(3):409-15. PubMed ID: 4310667
[TBL] [Abstract][Full Text] [Related]
23. Receptor-specific threshold effects of cyclic AMP are involved in the regulation of enzyme release and superoxide production from human neutrophils.
Lad PM; Goldberg BJ; Smiley PA; Olson CV
Biochim Biophys Acta; 1985 Aug; 846(2):286-95. PubMed ID: 2411298
[TBL] [Abstract][Full Text] [Related]
24. Factors influencing the response of human blood platelets to analogues of ADP which may act as partial agonists at the ADP receptor.
Egan CM; Fisher AP; Scrutton MC
Eur J Biochem; 1979 Mar; 95(1):127-37. PubMed ID: 110586
[TBL] [Abstract][Full Text] [Related]
25. Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances.
Whitaker MO; Wyche A; Fitzpatrick F; Sprecher H; Needleman P
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5919-23. PubMed ID: 230492
[TBL] [Abstract][Full Text] [Related]
26. Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors.
Cusack NJ; Hourani SM
Br J Pharmacol; 1982 May; 76(1):221-7. PubMed ID: 6282375
[TBL] [Abstract][Full Text] [Related]
27. Studies on antiplatelet effects of OP-41483, a prostaglandin I2 analog, in experimental animals. II. Mechanism of its antiplatelet effect.
Fujitani B; Wakitani K
Jpn J Pharmacol; 1990 May; 53(1):25-33. PubMed ID: 2161965
[TBL] [Abstract][Full Text] [Related]
28. Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5'-diphosphate in human platelets.
Hall DA; Hourani SM
Biochem Pharmacol; 1994 Mar; 47(6):1013-8. PubMed ID: 8147900
[TBL] [Abstract][Full Text] [Related]
29. 5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation.
Cusack NJ; Hourani SM
Br J Pharmacol; 1981 Mar; 72(3):443-7. PubMed ID: 7260485
[TBL] [Abstract][Full Text] [Related]
30. Effects of alpha 2-adrenoceptor agonists and of related compounds on aggregation of, and on adenylate cyclase activity in, human platelets.
Clare KA; Scrutton MC; Thompson NT
Br J Pharmacol; 1984 Jun; 82(2):467-76. PubMed ID: 6145472
[TBL] [Abstract][Full Text] [Related]
31. Prostacyclin stimulation of the activation of blood coagulation factor X by platelets.
Dutta-Roy AK; Ray TK; Sinha AK
Science; 1986 Jan; 231(4736):385-8. PubMed ID: 3001935
[TBL] [Abstract][Full Text] [Related]
32. Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin- and epinephrine-induced platelet stimulation.
Feoktistov IA; Paul S; Hollister AS; Robertson D; Biaggioni I
Am J Hypertens; 1992 Jun; 5(6 Pt 2):147S-153S. PubMed ID: 1321639
[TBL] [Abstract][Full Text] [Related]
33. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets.
Mills DC; Smith JB
Biochem J; 1971 Jan; 121(2):185-96. PubMed ID: 4330088
[TBL] [Abstract][Full Text] [Related]
34. Thrombin-induced increase in intracellular cyclic 3',5'-adenosine monophosphate in human platelets.
Droller MJ; Wolfe SM
J Clin Invest; 1972 Dec; 51(12):3094-103. PubMed ID: 4344994
[TBL] [Abstract][Full Text] [Related]
35. Multiple effects of guanine nucleotides on human platelet adenylated cyclase.
Tsai BS; Lefkowitz RJ
Biochim Biophys Acta; 1979 Sep; 587(1):28-41. PubMed ID: 486544
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human platelet adenylate cyclase by collagen fibres. Effect of collagen is additive with that of adrenaline, but interactive with that of thrombin.
Farndale RW; Winkler AB; Martin BR; Barnes MJ
Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):25-32. PubMed ID: 1311555
[TBL] [Abstract][Full Text] [Related]
37. Two mechanisms for inhibition of ADP-induced platelet shape change by 5'-p-fluorosulfonylbenzoyladenosine. Conversion to adenosine, and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase.
Mills DC; Figures WR; Scearce LM; Stewart GJ; Colman RF; Colman RW
J Biol Chem; 1985 Jul; 260(13):8078-83. PubMed ID: 2989276
[TBL] [Abstract][Full Text] [Related]
38. Do human platelets have opiate receptors?
Reches A; Eldor A; Vogel Z; Salomon Y
Nature; 1980 Nov; 288(5789):382-3. PubMed ID: 6253832
[TBL] [Abstract][Full Text] [Related]
39. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
[TBL] [Abstract][Full Text] [Related]
40. Cyclic 3',5'-adenosine monophosphate in human blood platelets. II. Effect of N6-2'-o-dibutyryl cyclic 3',5'-adenosine monophosphate on platelet function.
Salzman EW; Levine L
J Clin Invest; 1971 Jan; 50(1):131-41. PubMed ID: 4322665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
